Diagnostics in Immunology

Empowering Practices | Benefiting Patients

  • Immunological testing is a solution to the unmet need and timely diagnosis of immune disorders.

  • Amerimmune combines immunophenotyping flow cytometry testing, expert interpretation and recommendations.

  • Amerimmune testing empowers the private practitioner to optimally manage their patient population.

All immune evaluation reports will include a consultative analysis that is uniquely relevant to the individual patient. Recommendations are based upon the provided, clinical information and lab results only. Clinical correlation of the results by the treating physician is also necessary.

OUR STANDARD IMMUNOPHENOTYPING PANEL (SIP) IS TYPICALLY USED FOR RAPID SCREENING FOR AN IMMUNE DISORDER IN PATIENTS WITH SUSPECTED IMMUNE DISEASE, AS WELL AS MONITORING IMMUNODEFICIENCY. ADDITIONALLY, AMERIMMUNE’S IMMUNOPHENOTYPING PANEL SHEDS VALUABLE LIGHT ON YOUR PATIENTS’ RISK OF MORE SERIOUS COMPLICATIONS FROM SARS-COV2.

Markers include: lymphocyte subsets (CD3, CD4, CD8, CD16, CD20, CD56); T Cell panel - monitoring, activation markers, and memory (CD3, CD4, CD8, HLA-DR, CD25, CD57, TCR α/β, TCR γ/δ, CD294 CD45RO, CD45RA); B cell panel – maturation and isotype switching (CD5, CD19, CD20, CD21, IgG, IgA, IgD, IgM, CD27); Dendritic cells markers: % Dendritic cells (defined as CD3-/CD14-/CD16-/CD19-/CD20-/CD34-/CD56- and HLADR+) and subset markers CD303a and CD11c.

AMERIMMUNE’S COVID PHENOTYPING ASSAY (CPA) IS DESIGNED TO EVALUATE THE IMMUNE CELLS AND COMPONENTS THAT ARE CRITICAL IN THE HOST IMMUNE RESPONSE AND CONTROLLING INFLAMMATION, IDENTIFYING AREAS OF DEFICIENCY, OVERACTIVITY, AND DYSFUNCTION IN THE IMMUNE SYSTEM. CPA WILL REVEAL HIGH RISK FOR SEVERE DISEASE FROM SARS-COV-2 BY IDENTIFYING IMMUNE DEFICIENCIES AS PER CDC GUIDELINES.

Markers include: LAG-3, PD-1, Caspase 1 inhibitor, ICOS, HLA-DR, CD3, CD4, CD45RA, CD45RO, CD38, CD28, CD8, CD45, CXCR5, CCR5, CD39, CD127, CCR7, CD25, CD317, CD27, CD19, CD20

BASOPHIL ACTIVATION AND LYMPHOCYTE IMMUNOPHENOTYPING PANEL (BLIP or BAT COMMONLY REFERRED TO AS BASOPHIL ACTIVATION TESTING) is a functional assay that measures the degree of degranulation following stimulation with allergen or controls by flow cytometry. It correlates directly with histamine release. IT TESTS WITH SAFETy, and a high level of SPECIFICITY and sensitivity IN CONJUNCTION WITH A FOOD CHALLENGE. BAT reduces the need for in vivo procedures, such as intradermal tests and allergen challenges, which can cause allergic reactions of unpredictable severity. BASOPHIL TESTING OPTIMIZES MANAGEMENT OF FOOD ALLERGIC PATIENTS, ALLOWING FOR TARGETED THERAPY SUCH AS ORAL FOOD CHALLENGE OR ORAL IMMUNOTHERAPY. The results should be interpreted in the context of clinical history and other food allergy testing results. Learn more about it by reading our paper published in Allergy.

Markers include: Basophil Identification- IgE, CD123, CD193, Basophil Response- CD63, CD203c, and Lymphocyte Immune Phenotyping- CD3, CD4, CD8, CD16, CD20, CD45, CD45RO, CD56, CD294

Our Progenitor Eosinophil Immunophenotyping Panel (PEIP) identifies and semi-quantitates the eosinophil progenitor cells in the peripheral blood. In patients with eosinophilic derived inflammatory diseases, it is thought that eosinophils originating from hematopoietic stem cells located in the bone marrow are mobilized to sites of inflammation. It is at these peripheral sites of inflammation where the eosinophilic progenitor (EOP) cells differentiate and proliferate. PEIP offers your patients a minimally-invasive alternative to monitoring disease activity.

Markers include:

lineage: (CD2, CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, CD56, CD235a), CD45RA, CD125, CD123, CD38, CD34.

Reportable: CD45RA-CD43High+ % of all cells, CD45RA-CD34High+ Absolute Number (Cells/mL Blood), EOP cells-% of all cells, EOP cells-Absolute Number (Cells/mL Blood), Ratio of EOP cells: CD45RA-CD43High+, % of all Cells, Absolute number.

 

Amerimmune’s Caspase 1 Assay is a component of CPA that can be ordered independently.  Activation of Caspase-1 by the inflammasome is a critical component of the host response to infections.  This assay examines base and stimulated levels of activated caspase-1 to evaluate inflammation.

Markers include: CD39, CD3, CD4, CD45, CD45RO, Caspase 1 inhibitor and viability dye.

IL-12 is the signature cytokine for the Th1 immune response and deficiency can lead to increased susceptibility to mycobacterial diseases and Salmonella infections. The pSTAT4 assay reports the percentage of STAT4 phosphorylation in the CD3/CD4/CD45RO population in response to IL-12 stimulation at various time-points from 0-2 hours. A low response is an indicator of a deficient/compromised Th1 immune response. This assay is typically ordered as a follow up to the SIP assay evaluation.

Markers include: CD3, CD4, CD45RO, p-STAT4

Non-Validated Assay

The AKT/mTOR (through mTORC1) pathway is believed to play a significant role in initiating anti-apoptotic and pro-proliferative pathways in cells, while p38/MAPK plays a significant role in initiating pro-apoptotic pathways in cells.  Monocytes are a part of the innate immune system and influence the process of adaptive immunity. Monocytosis, an increase in the number of monocytes circulating in the blood, is indicative of a chronic inflammatory state and is observed in several autoimmune diseases.  The assay measures the basal phosphorylation status of AKT, mTOR, and p38/MAPK in monocytes and measures the response to LPS stimulation through quantification of AKT, mTOR, and p38/MAPK phosphorylation.

Markers include: CD14, CD16, HLADR, phosphor-p38, phosphor-AKT, phosphor mTOR